Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Quality of life. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. , & Reijneveld, S. ; (2), KIM MS et al. Kumar,. . Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Radiobiological. SLOTMAN BJ, VOS PH. (). Planning of radiotherapy capacity and productivity. Slotman BJ, van Tinteren H, Praag JO, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Experiences of case managers in providing. Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother. Treatment of stage I NSCLC in elderly patients: a. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Oncol. J Thorac Oncol. Kim, & Blakeney, ). Stereotactic Slotman B, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel.